Vistagen announces positive top-line results from phase 3 palisade-2 trial of fasedienol (ph94b) nasal spray in social anxiety disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (cns) disorders, today announced positive top-line results from its phase 3 palisade-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (ph94b) nasal spray in adults diagnosed with social anxiety disorder (sad). the trial met its primary e.
VTGN Ratings Summary
VTGN Quant Ranking